Target overview
Synonyms
CD30|TNFRSF8
Clinically Active Patent Light
CD30 / TNFRSF8
CD30 / TNFRSF8 is flagged as clinically active patent light based on 2 active trials across 3 sponsors and 0 patent-density signals in public data. This is a public-data screen, not a legal, clinical, or investment conclusion.
Clinical activity
Public trial footprint
Clinical trials: 3
Active trials: 2
Recruiting trials: 1
Known assets: 0
Sponsor activity
Competitive footprint
Unique sponsors: 3
Top sponsors: University Hospital, Caen | Memorial Sloan Kettering Cancer Center | National Cancer Institute (NCI)
Tumor types: Hodgkin Lymphoma | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
Patent-density signal summary
Patent layer
Signal count: 0
Recent signals: 0
Top assignees: Unknown
Signal types: Unknown
Scores and labels
Deterministic summary
Clinical crowding: 3/5 (Elevated)
Clinical maturity: 1/5 (Phase 1 Only)
Patent density: 0/5 (Low)
Momentum: 0/5 (Quiet)
Confidence: High
Limitations
Manual review still matters
This page summarizes public metadata patterns. It does not conclude patent scope, freedom to operate, clinical superiority, or commercial attractiveness.